An assessment of treatment history and its association with clinical outcomes and relapse in 155 pemphigus patients with response to a single cycle of rituximab.

摘要: Background Studies of pemphigus vulgaris and foliaceus patients treated with rituximab have used several different dosing protocols. Likewise, patients' clinical history varies in the length disease prior to initiation rituximab, previous immunosuppressants adjuvants during treatment. Objective We sought assess factors associated improved outcomes a greater duration from last dose time relapse responding single cycle rituximab. Methods We retrospectively evaluated published cases rituximab. Results One hundred fifty-five were evaluated. An increased number months before receiving treatment failure achieve complete remission. Patients using low-dose rheumatoid arthritis protocol (2 × 500 mg) experienced lower rate response decrease relapse. standard lymphoma (375 mg/m2 × 4 weeks) demonstrated There was no difference seen reaching vs. (1000 mg × 2). The use adjuvant plasma exchange or immunoadsorption an increase relapse. Conclusion Based on these observations, should not be recommended due inferior shortened